{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:04:54Z","timestamp":1773669894266,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00415-025-13507-0","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:28:40Z","timestamp":1765902520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Guillain\u2013Barr\u00e9 syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9933-7996","authenticated-orcid":false,"given":"Jean","family":"Cabon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Ducloie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basile","family":"Chretien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang\u00e9lique","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"13507_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381:1535\u20131546","journal-title":"N Engl J Med"},{"key":"13507_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290","journal-title":"N Engl J Med"},{"key":"13507_CR3","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC et al (2023) Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol Off J Am Soc Clin Oncol 41:1992\u20131998","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10336","key":"13507_CR4","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, KEYNOTE-716 Investigators (2022) Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 399(10336):1718\u20131729. https:\/\/doi.org\/10.1016\/S0140-6736(22)00562-1","journal-title":"Lancet"},{"key":"13507_CR5","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM et al (2022) Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 386:1973\u20131985","journal-title":"N Engl J Med"},{"key":"13507_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK et al (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med 385:683\u2013694","journal-title":"N Engl J Med"},{"key":"13507_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"issue":"4","key":"13507_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB (2020) Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 19(4):479\u2013488. https:\/\/doi.org\/10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"13507_CR9","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila N, Lehmann HC, Kuwabara S (2021) Guillain-Barr\u00e9 syndrome. Lancet 397:1214\u20131228","journal-title":"Lancet"},{"issue":"9","key":"13507_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","volume":"10","author":"BR Wakerley","year":"2014","unstructured":"Wakerley BR, Uncini A, Yuki N, GBS Classification Group, GBS Classification Group (2014) Guillain-barr\u00e9 and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol 10(9):537\u2013544. https:\/\/doi.org\/10.1038\/nrneurol.2014.138","journal-title":"Nat Rev Neurol"},{"issue":"18","key":"13507_CR11","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","volume":"30","author":"B van den Berg","year":"2013","unstructured":"van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC (2013) Mortality in Guillain-Barr\u00e9 syndrome. Neurology 30(18):1650\u20131654. https:\/\/doi.org\/10.1212\/WNL.0b013e3182904fcc","journal-title":"Neurology"},{"issue":"1","key":"13507_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/jns5.12051","volume":"19","author":"SK Darweesh","year":"2014","unstructured":"Darweesh SK, Polinder S, Mulder MJ, Baena CP, van Leeuwen N, Franco OH, Jacobs BC, van Doorn PA (2014) Health-related quality of life in Guillain-Barr\u00e9 syndrome patients: a systematic review. J Peripher Nerv Syst 19(1):24\u201335. https:\/\/doi.org\/10.1111\/jns5.12051","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"13507_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","volume":"83","author":"YA Rajabally","year":"2012","unstructured":"Rajabally YA, Uncini A (2012) Outcome and its predictors in Guillain\u2013Barr\u00e9 syndrome. J Neurol Neurosurg Psychiatry 83(7):711\u2013718. https:\/\/doi.org\/10.1136\/jnnp-2011-301882","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"13507_CR14","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1212\/wnl.51.4.1110","volume":"51","author":"BC Jacobs","year":"1998","unstructured":"Jacobs BC, Rothbarth PH, van der Mech\u00e9 FG, Herbrink P, Schmitz PI, de Klerk MA, van Doorn PA (1998) The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study. Neurology 51(4):1110\u20131115. https:\/\/doi.org\/10.1212\/wnl.51.4.1110","journal-title":"Neurology"},{"issue":"1","key":"13507_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9800488","volume":"2021","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang X, Zhao C (2021) Guillain-Barr\u00e9 syndrome-like polyneuropathy associated with immune checkpoint inhibitors: a systematic review of 33 cases. Biomed Res Int 2021(1):9800488. https:\/\/doi.org\/10.1155\/2021\/9800488","journal-title":"Biomed Res Int"},{"key":"13507_CR16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00415-020-10213-x","volume":"268","author":"K Okada","year":"2021","unstructured":"Okada K et al (2021) Polyradiculoneuropathy induced by immune checkpoint inhibitors: a case series and review of the literature. J Neurol 268:680\u2013688","journal-title":"J Neurol"},{"issue":"6","key":"13507_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\u00e9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C (2024) The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf 47(6):585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7","journal-title":"Drug Saf"},{"key":"13507_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/brain\/awac067","volume":"146","author":"RYS Keh","year":"2023","unstructured":"Keh RYS et al (2023) COVID-19 vaccination and Guillain-Barr\u00e9 syndrome: analyses using the National Immunoglobulin Database. Brain J Neurol 146:739\u2013748","journal-title":"Brain J Neurol"},{"key":"13507_CR19","doi-asserted-by":"publisher","first-page":"e2035","DOI":"10.1212\/WNL.0000000000207900","volume":"101","author":"H Bishara","year":"2023","unstructured":"Bishara H et al (2023) Association between Guillain-Barr\u00e9 syndrome and COVID-19 infection and vaccination: a population-based nested case-control study. Neurology 101:e2035\u2013e2042","journal-title":"Neurology"},{"key":"13507_CR20","doi-asserted-by":"publisher","first-page":"e2094","DOI":"10.1212\/WNL.0000000000207847","volume":"101","author":"S Le Vu","year":"2023","unstructured":"Le Vu S et al (2023) Risk of Guillain-barr\u00e9 syndrome following COVID-19 vaccines: a nationwide self-controlled case series study. Neurology 101:e2094\u2013e2102","journal-title":"Neurology"},{"key":"13507_CR21","doi-asserted-by":"publisher","first-page":"e2168","DOI":"10.1212\/WNL.0000000000009180","volume":"94","author":"C Grave","year":"2020","unstructured":"Grave C et al (2020) Seasonal influenza vaccine and Guillain-Barr\u00e9 syndrome: a self-controlled case series study. Neurology 94:e2168\u2013e2179","journal-title":"Neurology"},{"issue":"9876","key":"13507_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","volume":"381","author":"DA Salmon","year":"2013","unstructured":"Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, Cunningham F, Garman P, Greene SK, Lee GM, Vellozzi C, Yih WK, Gellin B, Lurie N (2013) Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 381(9876):1461\u20131468. https:\/\/doi.org\/10.1016\/S0140-6736(12)62189-8","journal-title":"Lancet"},{"issue":"12","key":"13507_CR23","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"J-E Salem","year":"2018","unstructured":"Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano J-P, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579\u20131589. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"13507_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6:865\u2013871","journal-title":"JAMA Oncol"},{"issue":"4","key":"13507_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM (1998) A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54(4):315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"13507_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","volume":"75","author":"K Bihan","year":"2020","unstructured":"Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem J-E (2020) Uses of pharmacovigilance databases: an overview. Therapie 75:591\u2013598","journal-title":"Therapie"},{"key":"13507_CR27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1017\/S0033291720000161","volume":"51","author":"B Chr\u00e9tien","year":"2021","unstructured":"Chr\u00e9tien B et al (2021) Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase\u00ae. Psychol Med 51:1459\u20131466","journal-title":"Psychol Med"},{"issue":"7","key":"13507_CR28","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/ejhf.1497","volume":"21","author":"S Ederhy","year":"2019","unstructured":"Ederhy S, Dolladille C, Thuny F, Alexandre J, Cohen A (2019) Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication. Eur J Heart Fail 21(7):945\u2013947. https:\/\/doi.org\/10.1002\/ejhf.1497","journal-title":"Eur J Heart Fail"},{"key":"13507_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A (2013) Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22:57\u201369","journal-title":"Stat Methods Med Res"},{"key":"13507_CR30","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00415-021-10404-0","volume":"268","author":"Q Fan","year":"2021","unstructured":"Fan Q, Hu Y, Wang X, Zhao B (2021) Guillain-Barr\u00e9 syndrome in patients treated with immune checkpoint inhibitors. J Neurol 268:2169\u20132174","journal-title":"J Neurol"},{"key":"13507_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000544","volume":"6","author":"A Abrahao","year":"2024","unstructured":"Abrahao A, Ten\u00f3rio PHdeM, Rodrigues M, Mello M, Nascimento OJM (2024) Guillain-barr\u00e9 syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data. BMJ Neurol Open 6:e000544","journal-title":"BMJ Neurol Open"},{"key":"13507_CR32","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK et al (2022) Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1:EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"13507_CR33","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA et al (2022) Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma. N Engl J Med 386:24\u201334","journal-title":"N Engl J Med"},{"key":"13507_CR34","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1111\/ene.15942","volume":"30","author":"C Yan","year":"2023","unstructured":"Yan C et al (2023) Predictors for the development of neurological immune-related adverse events of immune checkpoint inhibitors and impact on mortality. Eur J Neurol 30:3221\u20133227","journal-title":"Eur J Neurol"},{"issue":"1","key":"13507_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Manouchehri A, Haugh AM, Quach HT, Balko JM, Lebrun-Vignes B, Mammen A, Moslehi JJ, Salem J-E (2019) Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer 7(1):134. https:\/\/doi.org\/10.1186\/s40425-019-0617-x","journal-title":"J Immunother Cancer"},{"key":"13507_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","volume":"24","author":"M Xu","year":"2019","unstructured":"Xu M, Nie Y, Yang Y, Lu Y-T, Su Q (2019) Risk of neurological toxicities following the use of different immune checkpoint inhibitor regimens in solid tumors: a systematic review and meta-analysis. Neurologist 24:75\u201383","journal-title":"Neurologist"},{"key":"13507_CR37","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","volume":"53","author":"S-Q Tang","year":"2021","unstructured":"Tang S-Q et al (2021) The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8436 patients. Cancer Res Treat 53:339\u2013354","journal-title":"Cancer Res Treat"},{"key":"13507_CR38","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol 39:4073\u20134126","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"13507_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer JR et al (2021) Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435","journal-title":"J Immunother Cancer"},{"key":"13507_CR40","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33:1217\u20131238","journal-title":"Ann Oncol"},{"issue":"1","key":"13507_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1474-4422(23)00369-1","volume":"23","author":"A Farina","year":"2024","unstructured":"Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, Zekeridou A, Mu\u00f1iz-Castrillo S, Velasco R, Guidon AC, Joubert B, Honnorat J (2024) Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23(1):81\u201394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00369-1","journal-title":"Lancet Neurol"},{"issue":"16","key":"13507_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165774","volume":"11","author":"N Vilari\u00f1o","year":"2020","unstructured":"Vilari\u00f1o N, Bruna J, Kalofonou F, Anastopoulou GG, Argyriou AA (2020) Immune-driven pathogenesis of neurotoxicity after exposure of cancer patients to immune checkpoint inhibitors. Int J Mol Sci 11(16):5774. https:\/\/doi.org\/10.3390\/ijms21165774","journal-title":"Int J Mol Sci"},{"issue":"10045","key":"13507_CR43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"13","author":"HJ Willison","year":"2016","unstructured":"Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barr\u00e9 syndrome. Lancet 13(10045):717\u2013727. https:\/\/doi.org\/10.1016\/S0140-6736(16)00339-1","journal-title":"Lancet"},{"key":"13507_CR44","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721\u20131728","journal-title":"JAMA Oncol"},{"key":"13507_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad169","volume":"5","author":"A Farina","year":"2023","unstructured":"Farina A et al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun 5:fcad169","journal-title":"Brain Commun"},{"issue":"8","key":"13507_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102586","volume":"19","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Anquetil C, Manouchehri A, Benveniste O, Lambotte O, Lebrun-Vignes B, Spano JP, Ederhy S, Klatzmann D, Rosenzwajg M, Fautrel B, Cadranel J, Johnson DB, Moslehi JJ, Salem JE (2020) Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev 19(8):102586. https:\/\/doi.org\/10.1016\/j.autrev.2020.102586","journal-title":"Autoimmun Rev"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13507-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13507-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13507-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:58:21Z","timestamp":1773665901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13507-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["13507"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13507-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was conducted in accordance with the reporting guidelines for disproportionality analyses in drug safety signal detection utilizing ICSRs in pharmacovigilance (READUS-PV) guidelines","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"27"}}